Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2858398rdf:typepubmed:Citationlld:pubmed
pubmed-article:2858398lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2858398lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:2858398lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:2858398lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:2858398lifeskim:mentionsumls-concept:C0104350lld:lifeskim
pubmed-article:2858398lifeskim:mentionsumls-concept:C0205198lld:lifeskim
pubmed-article:2858398pubmed:issue2lld:pubmed
pubmed-article:2858398pubmed:dateCreated1985-5-23lld:pubmed
pubmed-article:2858398pubmed:abstractTextEffects of chloroquine, colchicine, leupeptin, taxol and vinblastine on the resialylation and degradation of human [125I]asialotransferrin type 3 were studied in rats. An improved experimental technique was applied that permitted the quantification of resialylated ligand produced by individual animals over 3 h by using deconvolution. All three microtubule inhibitors increased the proportion of the dose undergoing resialylation by 35-39%. In addition, colchicine, and, especially, vinblastine enhanced the overall recovery of the dose as protein-bound 125I. The dose recovery was also augmented by leupeptin without any concomitant change in resialylation. Chloroquine suppressed resialylation and this effect could only be partially lifted by the administration of colchicine. The blood of colchicine-treated rats possessed no resialylating activity toward the ligand even when supplemented with additional alkaloid in vitro. The observations support the view that the respective fractions of the ligand destined for resialylation and degradation can, to a certain extent, be varied independently of each other. The effects of short-term starvation (20 h) and refeeding (4 h) on these processes are also presented.lld:pubmed
pubmed-article:2858398pubmed:languageenglld:pubmed
pubmed-article:2858398pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:citationSubsetIMlld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2858398pubmed:statusMEDLINElld:pubmed
pubmed-article:2858398pubmed:monthAprlld:pubmed
pubmed-article:2858398pubmed:issn0014-4827lld:pubmed
pubmed-article:2858398pubmed:authorpubmed-author:CharlwoodP...lld:pubmed
pubmed-article:2858398pubmed:authorpubmed-author:RegoecziEElld:pubmed
pubmed-article:2858398pubmed:authorpubmed-author:ChindemiP APAlld:pubmed
pubmed-article:2858398pubmed:issnTypePrintlld:pubmed
pubmed-article:2858398pubmed:volume157lld:pubmed
pubmed-article:2858398pubmed:ownerNLMlld:pubmed
pubmed-article:2858398pubmed:authorsCompleteYlld:pubmed
pubmed-article:2858398pubmed:pagination495-503lld:pubmed
pubmed-article:2858398pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:meshHeadingpubmed-meshheading:2858398-...lld:pubmed
pubmed-article:2858398pubmed:year1985lld:pubmed
pubmed-article:2858398pubmed:articleTitleThe effects of cytotropic compounds on the resialylation of human asialotransferrin type 3 in the rat.lld:pubmed
pubmed-article:2858398pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2858398pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed